Skip to content
DISCOUNT! Back-to-Work Campaign: 50% off Yearly plans through September. Use code YEAR50

Mason Hawkins' Longleaf Partners exited its entire BIO position, 3.73% of the portfolio, held for ~3 years.

Sold out of a position that was 140,913 shares worth $39.28M as of the previous filing.
Published · Based on SEC filings

High impact
Position exited
2026 Q2

Bio-Rad Laboratories Inc (BIO) is gone from Mason Hawkins' Longleaf Partners portfolio as of June 30, 2026, according to the NPORT-P filed with the SEC on August 31, 2026. A quarter earlier the position was 141K shares worth about $39.3M, or 3.73% of the reported book. BIO had been in the portfolio for 3 years, since the quarter ended June 30, 2023.

What did the 2026 Q2 filing report for BIO?

As of June 30, 2026, from the NPORT-P filed August 31, 2026.

Before After
Shares 141K 0
Reported value $39.3M $0
Portfolio weight 3.73% 0%
Held since 2023 Q2 sold out in 2026 Q2
Quarters held 12

What did Mason Hawkins sell?

Mason Hawkins sold 141K shares of BIO between the quarter ended March 31, 2026 and June 30, 2026. The BIO exit was the 2nd largest of the quarter's 15 position changes by percent change to portfolio.

Where does BIO sit in the Mason Hawkins portfolio?

Before the sale, BIO carried 3.73% of the Mason Hawkins portfolio, below the fund's average stock position of 5%. The largest stock position is RYN at 7.74%. Next come MICC at 7.44% and PPLI at 7.42%. The three largest stocks together are 22.6% of the book. Across the 2026 Q2 portfolio, Mason Hawkins reported 17 stock positions, with 1 opened and 1 closed. The total portfolio value is about $1.1B, little changed from the prior quarter.

Mason Hawkins buys and sells, 2026 Q2

How long has Mason Hawkins held BIO?

Mason Hawkins held BIO for 3 years, from the quarter ended June 30, 2023 to March 31, 2026. The weight peaked at 5.06% in 2024 Q4. The share count had been unchanged the quarter before. Every reported trade is on the Mason Hawkins BIO trade history page.

Mason Hawkins shares of BIO by quarter

Did other funds buy or sell BIO in 2026 Q2?

Among the other tracked funds that had filed for 2026 Q2 as of August 31, 2026, 2 still hold BIO. One other tracked fund sold out of it this quarter as well. The largest buyer of BIO this quarter was Charles Bobrinskoy. The largest sellers were Parnassus Endeavor Fund and John W. Rogers Jr.. Every tracked holder of BIO is on the BIO ownership page.

FAQ

How many BIO shares did Mason Hawkins sell?

Mason Hawkins sold all 141K shares of BIO it reported a quarter earlier, worth about $39.3M.

When did Mason Hawkins first buy BIO?

Mason Hawkins first reported BIO in the quarter ended June 30, 2023.

How much of the Mason Hawkins portfolio was BIO?

BIO was 3.73% of the Mason Hawkins portfolio at the prior quarter-end, and 0% after the sale.

Did other funds sell BIO in 2026 Q2?

One other tracked fund sold out of BIO in 2026 Q2 and 1 trimmed it; 2 still hold it.

Source: based on original SEC filings

Figures are from the fund's N-PORT report, which lists its positions at period-end values.
Stocks mentioned
Alan Irwin
Alan Irwin
Valuesider analyst